AUTHORS : Elsaesser C Fraissinette Ade B. Greiner B Kolopp M Mahl A Medina J Meingassner J Nussbaumer P Picarles V Roman D Vogel B Winiski A LAV694, a new antiproliferative agent showing improved skin tolerability vs. clinical standards for the treatment of actinic keratosis 2003 Biochem Pharmacol. 2003 Nov 15;66(10):1885-95. | Preclinical Safety Department, Novartis Pharma AG, WSH.2881.P03, CH-4002 Basel, Switzerland.